SCHEMBL21884592

SCHEMBL21884592

N#Cc1ccc(O)c(C(=O)Oc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.58
ALOX15 P16050 1/20 0.58
HSD17B10 Q99714 1/20 0.58
MAPT P10636 5/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CHRM1 P11229 1/20 0.50
TBXA2R P21731 1/20 0.50
SLC6A2 P23975 1/20 0.50
PDE4A P27815 1/20 0.50
ADRA1A P35348 1/20 0.50
KDR P35968 1/20 0.50
SLC6A3 Q01959 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
EGFR P00533 2/20 0.48
NSD2 O96028 1/20 0.47
HNF4A P41235 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7970481 0.88 MAPT (0.61) HPGDALOX15HSD17B10MAPTLMNA
SCHEMBL11865229 0.79 HPGD (0.68) HPGDALOX15HSD17B10MAPTLMNA
SCHEMBL30864246 0.79 HPGD (0.68) HPGDALOX15HSD17B10MAPTLMNA
SCHEMBL24066336 0.78 EGFR (0.46) HPGDHSD17B10MAPTSMN1; SMN2EGFR
SCHEMBL31645743 0.78 TMPRSS4 (0.44) MAPTHNF4ATMPRSS4XDHSLC22A12
SCHEMBL11798342 0.78 HPGD (0.66) HPGDALOX15HSD17B10MAPTLMNA
SCHEMBL546514 0.78 CA12 (0.61) LMNASMN1; SMN2EGFRPTGS2TMPRSS4
SCHEMBL30902488 0.77 HNF4A (0.62) HPGDALOX15HSD17B10CYP3A4PDE4A
SCHEMBL131551 0.77 HNF4A (0.62) HPGDALOX15HSD17B10CYP3A4PDE4A
SCHEMBL19024884 0.77 HNF4A (0.55) HPGDALOX15HSD17B10MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 HPGD 879/4885ALOX15 4116/4885HSD17B10 1041/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 HPGD 3683/4885ALOX15 4735/4885HSD17B10 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.